

A Review of Ecopharmacovigilance Methods for Assessing the Environmental Risk of Pharmaceuticals

Rohit Shivcharan Patil¹, Dipali Kaduba Shinde², Dhiraj Santosh Patil³, Lohar Yogesh Suresh⁴, Yogesh Bapurao Wagh⁵

^{1,2,3,4,5,6}*Pharmacy, Indubai Bhadane Pratishthan College of Pharmacy Borkund*

Abstract - Ecopharmacovigilance (EPV) encompasses the scientific study and practical activities related to identifying, assessing, understanding, and preventing the environmental harm caused by pharmaceuticals. These drugs can infiltrate the environment through various pathways, leading to detrimental consequences. Examples of pharmaceuticals with documented negative impacts include

Diclofenac sodium: This drug, when consumed by scavengers like vultures feeding on treated carcasses, can be lethal.

Ethinyl oestradiol: This medication disrupts fish populations by "feminizing" male fish.

Ivermectin: This treatment can hinder the growth of dung beetles.

Fluoxetine: This antidepressant has been linked to behavioral changes in shrimp.

Antibiotic use: The widespread use of antibiotics contributes to the emergence of antibiotic-resistant bacteria in the environment. Several corrective measures can be implemented to lessen the influx of pharmaceuticals into the environment. **Reduced pharmaceutical waste and Minimizing the amount of unused or expired medication produced.**

Enhanced wastewater treatment: Upgrading sewage treatment plants to more effectively remove pharmaceuticals from wastewater. **Green pharmacy initiatives for Promoting the development and use of medications with a lower environmental footprint.**

Improved medication disposal systems: Creating more accessible and user-friendly systems for safe disposal of unwanted medications. Regulatory bodies have adopted various strategies to address the environmental impact of pharmaceuticals. These include in environmental risk assessment (ERA). This process evaluates the potential environmental hazards associated with new drugs before their approval.

Resource Conservation and Recovery Act (RCRA): This legislation establishes regulations for the management of hazardous waste, including some types of pharmaceutical waste. Risk mitigation measures these are specific actions taken to minimize the environmental

risks posed by existing medications. By monitoring the effects of drugs not only on human health but also on the environment, we can ensure a more sustainable future for both.

Keywords - Ecopharmacovigilance, pharmaceuticals, environment, green pharmacy

INTRODUCTION

Ecopharmacovigilance (EPV) is a burgeoning discipline within environmental science and pharmacology that concentrates on the identification, evaluation, comprehension, and mitigation of adverse effects of pharmaceuticals on the environment. It expands the scope of pharmacovigilance, which traditionally focuses on the safety of drugs for humans, to encompass the environmental consequences of pharmaceuticals.

Key Concepts and Objectives

1) Detection and Monitoring:

Environmental Monitoring: EPV involves tracking pharmaceutical residues in various environmental compartments such as water, soil, and air.

Surveillance Programs: Setting up surveillance programs to detect the presence and concentration of pharmaceuticals in the environment.

2) Assessment:

Risk Assessment: Assessing the potential risks of pharmaceutical residues to ecosystems and human health.

Ecotoxicology Studies: Performing studies to understand the toxicity of pharmaceuticals on aquatic and terrestrial organisms.

3) Understanding:

Fate and Transport: Investigating how pharmaceuticals move and transform in the environment.

Mechanisms of Action: Understanding the mechanisms through which pharmaceuticals impact non-target organisms.

4) Prevention and Mitigation:

Regulation and Policy: Developing and enforcing regulations to minimize the release of pharmaceuticals into the environment.

Waste Management: Enhancing pharmaceutical waste management practices to prevent contamination.

Green Pharmacy: Promoting the development of environmentally friendly pharmaceuticals that are less persistent and toxic in the environment.



Sources of Pharmaceutical Contamination

1. **Human Excretion:** Pharmaceuticals consumed by humans are often excreted unchanged or as metabolites through urine and feces, which can enter wastewater systems.

2. **Manufacturing and Production:** Effluents from pharmaceutical manufacturing plants can contain high concentrations of active pharmaceutical ingredients (APIs).

3. **Improper Disposal:** Unused or expired medications that are improperly disposed of, such as being flushed down toilets or thrown into regular trash, can lead to environmental contamination.

4) **Agricultural Use:** Veterinary pharmaceuticals used in livestock can enter the environment through runoff from farms or through the application of manure as fertilizer.

Environmental Impact of Pharmaceuticals

1. **Aquatic Environments:** Pharmaceuticals can affect aquatic organisms at low concentrations, leading to issues like hormonal disruption in fish and other wildlife.

2. **Soil Contamination:** Pharmaceutical residues can accumulate in soil, affecting soil microorganisms

and potentially entering the food chain through crops.

3. **Antimicrobial Resistance:** The presence of antibiotics in the environment can contribute to the development of antimicrobial resistance, posing a significant public health risk.

Case Studies and Examples

Diclofenac and Vultures: The use of the veterinary drug diclofenac led to the mass decline of vulture populations in South Asia due to kidney failure caused by the drug. **Hormonal Disruptors:** Estrogens from birth control pills and hormone replacement therapies have been linked to the feminization of male fish in contaminated water bodies. **Ecopharmacovigilance** is a growing field, but here are a couple of prominent case studies that highlight its importance

Diclofenac and Vultures in India: Diclofenac, a pain medication for humans, was found to be lethal to vultures when they fed on carcasses of treated livestock. This resulted in a massive decline in vulture populations in India, disrupting the ecosystem's natural carrion removal process [1]. This case led to stricter regulations on veterinary use of diclofenac.

Estrogen in Water and Fish Feminization: Estrogen-based drugs, used in birth control pills and hormone replacement therapy, can enter waterways through sewage treatment plants. This can lead to feminization of male fish, disrupting their reproduction and impacting entire ecosystems. This case highlights the need for better wastewater treatment and eco-friendly drug development.

Examples of ecopharmacovigilance Practices:

1) **Monitoring Pharmaceuticals in Water:** Studies are being conducted to measure the presence of various pharmaceuticals in water bodies. This data helps identify potential risks and prioritize further investigation.

2) **Tracking Antibiotic Resistance:** Ecopharmacovigilance can monitor the emergence of antibiotic-resistant bacteria in the environment due to overuse of antibiotics in both human and veterinary medicine.

3) **Developing Environmentally Friendly Drugs:** Pharmaceutical companies are researching ways to design drugs that are more easily broken down by

natural processes, minimizing their environmental impact.

Ecological Impact of Pharmaceuticals:

Sources of Pharmaceutical Pollution:

Improper Disposal: Unused or expired medications flushed down the toilet or thrown in the trash can end up in waterways and landfills, contaminating water and soil.

Excretion: When we take medicines, our bodies don't fully absorb them all. What's left gets excreted and can enter sewage systems, potentially reaching waterways.

Manufacturing Waste: The production of pharmaceuticals generates wastewater containing chemicals and drug residues, which can harm aquatic life if not properly treated.



Environmental Effects:

Disruption of Ecosystems: Pharmaceuticals can disrupt the delicate balance of aquatic ecosystems. Trace amounts can affect wildlife in various ways, impacting their

Reproduction: Hormones and other medications can interfere with fish and amphibian reproduction.

Behavior: Antidepressants and other drugs can alter animal behavior, making them more susceptible to predators.

Development: Certain drugs can cause developmental problems in aquatic organisms.

Antimicrobial Resistance: The widespread use of antibiotics in humans and animals contributes to the rise of antibiotic-resistant bacteria in the environment. These "superbugs" become more difficult to treat, posing a threat to both human and animal health.

Examples of Contamination:

A 2022 study revealed that pharmaceutical pollution threatens "environmental and/or human health in more than a quarter of the studied locations" across various rivers worldwide.

Addressing the Issue: Safer Disposal Practices: Proper disposal programs for unused medications are essential to minimize environmental contamination.

Eco-friendly Drug Development: The pharmaceutical industry is exploring ways to design drugs that biodegrade more readily, reducing their environmental impact.

Improved Wastewater Treatment: Upgrading wastewater treatment facilities to remove pharmaceuticals more effectively is crucial.

Regulation and Monitoring: Stricter regulations on pharmaceutical manufacturing and disposal, along with ongoing monitoring of environmental levels, are necessary. Regulatory frameworks play a critical role in establishing and maintaining a robust ecopharmacovigilance system. Here's how they contribute:

The Role of Regulatory Frameworks

1. Standardization and Data Collection:

Regulatory frameworks define clear guidelines for conducting environmental risk assessments (ERA) of pharmaceuticals before they reach the market.

These guidelines establish standardized methods for testing potential environmental impacts, facilitating data collection and comparison.

2. Risk Management and Mitigation:

Frameworks can mandate specific actions based on the identified risks. This could include restrictions on the use of certain drugs in specific contexts (e.g., limitations on veterinary antibiotics). Requirements for safer disposal practices (e.g., take-back programs for unused medications). Development plans for more environmentally friendly alternatives.

3. Improved Monitoring and Reporting: Regulations can require pharmaceutical companies and healthcare providers to report suspected environmental impacts associated with drug use.

This data is crucial for identifying emerging problems and informing future risk assessments and policy changes.

Examples of Regulatory Frameworks: The European Union has a well-developed regulatory framework for ecopharmacovigilance. The EU Water Framework Directive sets standards for water quality and requires monitoring of pharmaceutical residues. The United States Environmental Protection Agency has guidelines for conducting ERAs on new drugs and pesticides.

Challenges and Considerations:

Although some regions have implemented frameworks, global uniformity remains elusive. Striking a balance between the necessity of efficacious medications and safeguarding the environment necessitates meticulous consideration.

CONCLUSION

The burgeoning presence of pharmaceuticals in the environment poses a significant threat to ecological health and potentially even human well-being. Ecopharmacovigilance emerges as a powerful tool to combat this issue by monitoring the environmental impact of drugs and informing strategies to mitigate risks.

Despite ongoing challenges, such as developing robust monitoring methods and integrating ecopharmacovigilance seamlessly into existing regulatory frameworks, the potential benefits of this field are immense. By promoting responsible practices in drug development, use, and disposal, ecopharmacovigilance can pave the way for a more sustainable approach to pharmaceuticals. This will not only safeguard ecosystems but also contribute to the overall health of our planet and its inhabitants.

REFERENCE

- [1] Ecopharmacovigilance: Perspectives, concepts, applications, and relationships in modern context <https://jpadr.com/index.php/jpadr/article/view/19> by Velo, G. (2006) offers a good overview of the field.
- [2] Ecopharmacovigilance: A review of cause, impact, and remedies [ResearchGate]
- [3] Environmental Risk Assessment of Pharmaceuticals by Boxall, A. B. A. et al. (2013) [Environmental Science & Technology] (Focuses on risk assessment methods)
- [4] Ecological effects of pharmaceuticals in freshwater ecosystems by Heberer, T. (2022) [Environmental Science and Pollution Research] (Focuses on ecological impacts)
- [5] Ecopharmacovigilance: Multidisciplinary Approaches to Environmental Safety of Medicines by Gomez-Olivan, L. M. (2018) (Provides in-depth analysis)

- [6] Environmentally Persistent Pharmaceutical Pollutants (EPPPs) [UNEP Website] by the United Nations Environment Programme (UNEP) (Discusses pharmaceutical pollution)
- [7] Look for resources from regulatory bodies in your region that deal with ecopharmacovigilance (e.g., US Environmental Protection Agency)
- [8] Ecopharmacovigilance: Multidisciplinary Approaches to Environmental Safety of Medicines (Book) by Gomez-Olivan, L. M. (2018) provides in-depth
- [9] The International Society of Pharmacovigilance (ISoP) <https://isoponline.org/>
- [10] The United Nations Environment Programme (UNEP) <https://www.unep.org/topics/chemicals-and-pollution-action/pollution-and-health/environmentally-persistent>